T2	Participants 47 116	with or without human interferon-beta, for advanced colorectal cancer
T1	Participants 274 331	patients with unresectable, advanced colorectal carcinoma
T3	Participants 333 387	Forty-nine chemotherapy-naive patients were randomized
